

# Group Benefits

## Drug Prior Authorization

### Dupilumab (Dupixent)

The purpose of this form is to obtain the medical information required to assess your request for a drug on the Prior Authorization list under your drug plan benefit coverage. To avoid delays in processing your request, please ensure that all information, including contact information is complete. Completion of this form is not a guarantee of approval. If you have already purchased the drug, please attach all original receipts along with an **Extended Health Care Claim** form. All costs incurred to complete this form are the plan member's responsibility. If you are registered for the Plan Member Secure Site and have provided an email address, you will receive an email notification when the prior authorization decision is available on your claims statement. If you are not registered on the Plan Member Secure Site, you will be notified of the prior authorization decision by mail.

**Important: Please ensure the most current unaltered version of the form is completed and signed. To download the most recent version of the Drug Prior Authorization form go to [www.manulife.ca](http://www.manulife.ca)**

<b>1 Plan member and patient information</b>  To be completed by plan member	Plan contract number	Plan member certificate number	Plan sponsor		
	Plan member name (first, middle initial, last)			Date of birth (dd/mmm/yyyy)	
	Plan member address (number, street and apt.)		City or town	Province	Postal code
	Patient name (first, middle initial, last)		Patient date of birth (dd/mmm/yyyy)	Relationship to plan member	
	Patient's preferred daytime phone number		Patient's email address (optional)		
	Does the patient have drug coverage under any other group plan?				<input type="radio"/> Yes <input type="radio"/> No
	If yes, Name of insurance company				
	Plan contract number		Plan member certificate number		
	Is this drug covered under the other group plan?				<input type="radio"/> Yes <input type="radio"/> No
	If <i>no</i> , why was the drug declined by the other group plan? Please attach the other group plan decline notice (typically a letter or statement). We need this decline notice to see if this drug can be approved. If this is a renewal a <b>current</b> decline notice is required.				
Did your plan sponsor recently transfer your drug benefits to Manulife?				<input type="radio"/> Yes <input type="radio"/> No	
Before joining Manulife, were you receiving coverage for this drug through your previous insurance company?				<input type="radio"/> Yes <input type="radio"/> No	
If yes, Attach proof of payment (a copy of a pharmacy receipt showing payment from prior insurance company or an Explanation of Benefits from the prior insurance company). Proceed to section 7.					
If <i>no</i> applies to any of the above two questions, Proceed to section 2.					
<b>2 Provincial Plans</b>  To be completed by prescribing physician	Most provinces offer some form of drug coverage to their residents. Your Manulife drug plan supplements the coverage provided by provincial plans. It is important that you or your doctor (if required) apply to the applicable provincial program to ensure there are no delays in your drug reimbursement.				
	Check with your doctor or login to the <b>Manulife Provincial Drug Plans Resource Centre</b> on our Plan Member Secure Site at <a href="http://www.manulife.ca/planmember">www.manulife.ca/planmember</a> to confirm if the drug you have been prescribed may be eligible for coverage under a provincial plan. If the drug you have been prescribed is listed under a provincial program, you will need to apply to the program before consideration can be given under your Manulife drug plan.				
	Has application been made to the provincial program for coverage?				
				<input type="radio"/> Yes <input type="radio"/> No	
If <i>no</i> , why?					

<p><b>2 Provincial Plans (continued)</b></p> <p>To be completed by prescribing physician</p>	<p>Has the patient been approved for coverage by the provincial program for this drug? <input type="radio"/> Yes <input type="radio"/> No</p> <p>If <i>no</i>, advise why the request was declined</p> <p><b>In Ontario, for patients that qualify for coverage under the Exceptional Access Program (EAP), if the drug is an EAP drug, a copy of the approval or denial from EAP must be submitted with this form so Manulife can complete the assessment of this request.</b></p>
<p><b>3 Patient Assistance Programs</b></p> <p>To be completed by plan member</p>	<p>Have you enrolled in the Patient Assistance Program? <input type="radio"/> Yes <input type="radio"/> No</p> <p>If yes, please provide your Patient Assistance Program ID Number: Case Manager name and contact details</p>
<p><b>4 Medical information</b></p> <p>To be completed by prescribing physician</p>	<p>Drug strength and dosage</p> <p>Where will the treatment be administered?  <input type="radio"/> Home    <input type="radio"/> MD Office    <input type="radio"/> Private Clinic    <input type="radio"/> Hospital/In-patient    <input type="radio"/> Hospital/Out-patient</p> <p>Is the MD office located in a hospital? <input type="radio"/> Yes <input type="radio"/> No</p> <p>Will the drug be administered in the MD office or in another area of the hospital? (describe below)</p> <p>If the treatment is <b>not</b> being administered at home, please provide:  Name of private clinic/hospital <span style="float: right;">Telephone number</span></p> <p>Address (number, street and apt.) <span style="margin-left: 150px;">City or town</span> <span style="margin-left: 100px;">Province</span> <span style="margin-left: 100px;">Postal code</span></p> <p><b>Please select the diagnosis for which the drug has been prescribed and respond to the corresponding questions.</b></p> <p><input type="radio"/> <b>Atopic Dermatitis (moderate to severe)</b></p> <p><input type="radio"/> <b>Initial Criteria</b></p> <p>Please provide the following:  Physicians Global Assessment (PGA)    Eczema Area and Severity Index (EASI)    Body Surface Area Involvement (BSAI)</p> <p>Has patient had an inadequate/suboptimal response or is allergic/intolerant to medium/high potency topical corticosteroids (e.g., amcinonide, betamethasone valerate, clobetasone butyrate, desoximetasone, flucinonide, diflucortolone valerate, flucinolone acetonide, mometasone furoate, triamcinolone acetonide)? <input type="radio"/> Yes <input type="radio"/> No</p> <p>Has patient had an inadequate/suboptimal response or is allergic/intolerant to topical calcineurin inhibitors (e.g., cyclosporine, tacrolimus)? <input type="radio"/> Yes <input type="radio"/> No</p> <p>Has patient enrolled in the Freedom Support Program? <input type="radio"/> Yes <input type="radio"/> No</p> <p>If <i>no</i>, please contact the <b>Freedom Support Program</b> at 1-844-216-1181 and complete section 3. Not completing section 3 may delay the processing of your request.</p> <p><b>Note: Approvals for prior authorization drugs may be subject to a time limitation. If applicable, you will be required to provide additional information to Manulife to assess continued coverage. You will be advised of the approval duration at the time of approval.</b></p> <p><input type="radio"/> <b>Renewal Criteria</b></p> <p>Has the patient experienced clinical benefit from treatment (e.g., improvement in PGA score from baseline, improvement in EASI score from baseline, etc.)? <input type="radio"/> Yes <input type="radio"/> No</p> <p><b>Note: Approvals for prior authorization drugs may be subject to a time limitation. If applicable, you will be required to provide additional information to Manulife to assess continued coverage. You will be advised of the approval duration at the time of approval.</b></p>

**4 Medical information (continued)**

To be completed by prescribing physician

**Chronic Rhinosinusitis with Nasal Polyposis**

**Initial Criteria**

Will Dupixent be used as add-on maintenance treatment with an intranasal corticosteroid?  Yes  No

Is the disease inadequately controlled by systemic corticosteroids and/or surgery?  Yes  No

Has patient enrolled in the Freedom Support Program?  Yes  No

If *no*, please contact the **Freedom Support Program** at 1-844-216-1181 and complete section 3. Not completing section 3 may delay the processing of your request.

**Note: Approvals for prior authorization drugs may be subject to a time limitation. If applicable, you will be required to provide additional information to Manulife to assess continued coverage. You will be advised of the approval duration at the time of approval.**

**Renewal Criteria**

Has the patient experienced clinical benefit from treatment?  Yes  No

Will Dupixent be used as an add-on maintenance treatment with intranasal corticosteroids?  Yes  No

**Note: Approvals for prior authorization drugs may be subject to a time limitation. If applicable, you will be required to provide additional information to Manulife to assess continued coverage. You will be advised of the approval duration at the time of approval.**

**Asthma**

**Initial Criteria**

Will Dupixent be used as add-on maintenance treatment?  Yes  No

Is asthma either severe with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma?  Yes  No

Has patient enrolled in the Freedom Support Program?  Yes  No

If *no*, please contact the **Freedom Support Program** at 1-844-216-1181 and complete section 3. Not completing section 3 may delay the processing of your request.

**Note: Approvals for prior authorization drugs may be subject to a time limitation. If applicable, you will be required to provide additional information to Manulife to assess continued coverage. You will be advised of the approval duration at the time of approval.**

**Renewal Criteria**

Has the patient experienced clinical benefit from treatment?  Yes  No

Will Dupixent be used as an add-on maintenance treatment?  Yes  No

**Note: Approvals for prior authorization drugs may be subject to a time limitation. If applicable, you will be required to provide additional information to Manulife to assess continued coverage. You will be advised of the approval duration at the time of approval.**

**Any other diagnosis**

Please provide the specific diagnosis and any Canadian clinical research that supports the use of this drug in your patient's context.



**7 Authorization and Plan member signature (continued)**

To be signed by plan member

**I understand:**

- If my Manulife plan recommends purchasing a drug that requires prior authorization from a preferred pharmacy or provider, a case manager may contact me, my doctor and/or patient assistance program to arrange to have my prescription(s) transferred to the preferred pharmacy or provider.
- That except where there are contractual restrictions, Manulife employees, authorized organizations, service providers and reinsurers are located both within Canada and outside of Canada. Therefore, my Personal Information may be subject to interprovincial or cross-border transfers for the Purposes and may be subject to the laws of those jurisdictions.
- I may withdraw my consent for certain uses of my Personal Information, subject to legal and contractual restrictions. If I do so, Manulife may treat my withdrawal of consent as a request to dismiss, rescind or terminate my claim.

**I agree:**

- A photocopy or electronic version of this consent is valid.
- I have the right to access and verify my Personal Information maintained in Manulife's files and to request any factually inaccurate Personal Information be corrected, if appropriate.
- Requests can be sent to: Privacy Officer Manulife, P.O. Box 1602, Del Stn 500-4-A, Waterloo, Ontario N2J 4C6 or Canada\_Privacy@manulife.ca.
- For more information, I can review the [Personal Information Statement for Employers' Group Benefits Plans](#) and the [Canadian Privacy Policy](#).

**I confirm that:**

- The information I have given in this request is true and accurate.
- By signing, I give permission to and/or confirm that I have obtained the individual's consent for the collection, use, disclosure or otherwise processing of the individual's Personal Information for the Purposes (as these terms are defined above).

Plan member's signature	Date signed (dd/mmm/yyyy)
-------------------------	---------------------------

Protecting your personal information is important to us. People who can see your personal information are:

- Manulife employees who need to see your information to do their jobs.
- People you've given permission to.

To find out more about Manulife's privacy policy please see [manulife.ca](http://manulife.ca)

**8 Mailing instruction**

Use the Submit a Claim Feature on the Plan Member Secure Site **OR** mail or fax your completed form to the appropriate address:

**If you live in Quebec:**

Manulife Group Benefits Health Claims  
Attention Prior Authorization Team  
PO BOX 2580, STATION B  
MONTREAL QC H3B 5C6

Fax: 1-855-752-0404

**If you live outside Quebec:**

Manulife Group Benefits Health Claims  
Attention Prior Authorization Team  
PO BOX 1653  
WATERLOO ON N2J 4W1

Fax: 1-855-752-0404

Please retain a photocopy for your files.